表紙
市場調查報告書
商品編碼
1024232

異位性皮膚炎:現在及今後的市場機會,流行病學研究,市場動態,開發平台分析,r-NPV分析

Atopic Dermatitis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 263 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供異位性皮膚炎的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病的概要與流行病學研究

第4章 異位性皮膚炎的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 異位性皮膚炎競爭空間的交易活動

第7章 異位性皮膚炎管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPHME014

GervanoRA's pipeline analysis and opportunity assessment report "Atopic Dermatitis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Atopic Dermatitis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Atopic Dermatitis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Atopic Dermatitis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Atopic Dermatitis Market (2020) and the Forecasted Atopic Dermatitis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Atopic Dermatitis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Atopic Dermatitis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Atopic Dermatitis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: ATOPIC DERMATITIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF ATOPIC DERMATITIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF ATOPIC DERMATITIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS) 2020-2030, MILLION
  • TABLE 03: TOP 10 DEALS RANKED BY THE DEAL AMOUNT
  • TABLE 04: MAJOR LICENSING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 05: MAJOR ACQUISITIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 06: MAJOR AGREEMENTS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 07: MAJOR COLLABORATIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 08: MAJOR FINANCING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
  • TABLE 09: ATOPIC DERMATITIS DEALS IN 2020
  • TABLE 10: US FDA APPROVED DRUGS SINCE 2010
  • TABLE 11: ATOPIC DERMATITIS APPROVED DRUGS (EX-US) SINCE 2010
  • TABLE 12: ATOPIC DERMATITIS PHASE 3 MOLECULES
  • TABLE 13: ATOPIC DERMATITIS PHASE 2 MOLECULES
  • TABLE 14: ATOPIC DERMATITIS PHASE 1 MOLECULES
  • TABLE 15: ATOPIC DERMATITIS PRECLINICAL MOLECULES
  • TABLE 16: ATOPIC DERMATITIS EARLY R&D STAGE MOLECULES
  • TABLE 17: ATOPIC DERMATITIS INACTIVE AND DISCONTINUED MOLECULES
  • TABLE 18: ATOPIC DERMATITIS PIPELINE ANALYTICS BY TOPICAL ROA
  • TABLE 19: ATOPIC DERMATITIS PIPELINE ANALYTICS BY ORAL ROA
  • TABLE 20: ATOPIC DERMATITIS PIPELINE ANALYTICS BY INJECTABLE ROA
  • TABLE 21: ATOPIC DERMATITIS PIPELINE ANALYTICS, IMMUNOMODULATORS
  • TABLE 22: ATOPIC DERMATITIS PIPELINE ANALYTICS, PDE4 INHIBITORS
  • TABLE 23: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-INFLAMMATORY
  • TABLE 24: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-MICROBIAL
  • TABLE 25: ATOPIC DERMATITIS PIPELINE ANALYTICS, JAK INHIBITORS

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: GLOBAL ATOPIC DERMATITIS MARKET BY GEOGRAPHY 2020 V/S 2030
  • FIGURE 02: GLOBAL ATOPIC DERMATITIS MARKET 2020-2030: MARKET SNAPSHOT
  • FIGURE 03: ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2020
  • FIGURE 04: ATOPIC DERMATITIS MARKET BY ROA, 2020
  • FIGURE 05: KEY EVENTS IN ATOPIC DERMATITIS AREA
  • FIGURE 06: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS), IN MILLION
  • FIGURE 07: ATOPIC DERMATITIS DEALS, GEOGRAPHY SPLIT-UP
  • FIGURE 08: ATOPIC DERMATITIS THERAPEUTIC AREA DEALS OVERVIEW
  • FIGURE 09: ATOPIC DERMATITIS DEALS ANNUAL FREQUENCY, 2011-2020
  • FIGURE 10: ATOPIC DERMATITIS DRUG PIPELINE, HSD SPLIT
  • FIGURE 11: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 12: ATOPIC DERMATITIS DRUG PIPELINE SPLIT, MAJOR APPROVAL MARKETS
  • FIGURE 13: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 14: TOPICALS BY HSD SPLIT-UP
  • FIGURE 15: ORALS BY HSD SPLIT-UP
  • FIGURE 16: PIPELINE ANALYTICS BY INJECTABLES, SPLIT BY TECHNIQUE USED
  • FIGURE 17: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 18: ATOPIC DERMATITIS DRUG CLASSES SCENARIO
  • FIGURE 19: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD
  • FIGURE 20: JAK INHIBITORS SPLIT BY HSD